Rosatom Wants To Test The Drug To Detect Complications In Covid-19
Scientists of the Russian nuclear industry want to conduct preclinical studies they have developed a promising radiopharmaceutical for diagnosis of the lung condition severe deficiencies, including observed on the background of coronavirus infection, the materials on the procurement website of Rosatom state Corporation.
According to these materials, specialists of the "Khlopin radium Institute" (Saint Petersburg, part of the scientific division of Rosatom), by order of the management company of the scientific division of the nuclear state Corporation JSC "Science and innovation," should prepare a technical specification for preclinical research of a bifunctional innovative radiopharmaceutical drug pentacarbonyl iodide technetium-99m for the diagnosis of perfusion and lung ventilation.
For a complete study of the condition of the lungs using radiopharmaceuticals, two procedures are used: intravenous administration of a suitable drug (when studying perfusion - blood flow in the lung tissue) and inhalation of a gaseous radioactive drug (when studying ventilation - the process of air exchange between the lungs and the atmosphere). This method of diagnosis is necessary to detect such dangerous diseases as pulmonary embolism, hypertension of the small circle of blood circulation, shoulder vein thrombosis, chronic obstructive pulmonary disease, etc.
A separate big task for medicine in recent years has become the diagnosis of lung conditions in patients with coronavirus infection, one of the most dangerous complications of which is pulmonary embolism.
Currently, conducting a full lung examination for several reasons is a quite complex and expensive procedure. Thus, the search for a drug that allows you to study both perfusion and ventilation is an urgent task, the solution of which will help to significantly simplify and reduce the cost of diagnosis.
Developed at the radium Institute, the new drug technetium pentacarbonyl iodide-99m (pcit-99mTc), as shown by preliminary studies on laboratory animals, accumulates in the lung tissue with high selectivity and is suitable for studying both perfusion and ventilation. At the same time, the PACKAGE-99mTc lacks the disadvantages inherent in radiopharmaceuticals drugs currently used for lung research. As noted in the terms of reference for the current work, previously such a drug did not exist.
Preliminary experiments on model animals have shown that the new drug is not toxic. The introduction of pkit-99mTc into clinical practice will, on the one hand, significantly reduce the cost of lung diagnostics, and on the other hand, eliminate the disadvantages of lung drugs currently used, the technical task says. Preclinical research is planned to be conducted at the St. Petersburg Russian scientific center of radiology and surgical technologies named after academician Granov of the Ministry of the health of the Russian Federation.